Colgate-Palmolive (NYSE:CL) SVP John J. Huston sold 10,170 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $71.05, for a total value of $722,578.50. Following the completion of the sale, the senior vice president now owns 48,965 shares in the company, valued at approximately $3,478,963.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of Colgate-Palmolive stock opened at $71.37 on Friday. Colgate-Palmolive has a 12-month low of $57.41 and a 12-month high of $76.41. The stock has a market cap of $61.51 billion, a P/E ratio of 25.15, a P/E/G ratio of 4.61 and a beta of 0.76. The company has a quick ratio of 0.78, a current ratio of 1.13 and a debt-to-equity ratio of 32.25. The business’s 50 day moving average is $72.54 and its 200-day moving average is $69.90.
Colgate-Palmolive (NYSE:CL) last posted its earnings results on Friday, July 26th. The company reported $0.72 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.72. The business had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.88 billion. Colgate-Palmolive had a negative return on equity of 10,821.98% and a net margin of 14.77%. The firm’s revenue was down .5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.77 EPS. On average, sell-side analysts expect that Colgate-Palmolive will post 2.84 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, August 15th. Investors of record on Thursday, July 18th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 2.41%. The ex-dividend date of this dividend was Wednesday, July 17th. Colgate-Palmolive’s payout ratio is presently 57.91%.
Several equities research analysts have commented on CL shares. Wells Fargo & Co boosted their target price on Colgate-Palmolive from $68.00 to $70.00 and gave the company a “market perform” rating in a research note on Monday, July 29th. Morgan Stanley upped their price objective on Colgate-Palmolive from $72.00 to $74.00 and gave the stock an “equal weight” rating in a research note on Monday, July 29th. Piper Jaffray Companies began coverage on Colgate-Palmolive in a research note on Tuesday. They set an “overweight” rating on the stock. UBS Group upped their price objective on Colgate-Palmolive from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Finally, Bank of America set a $80.00 price objective on Colgate-Palmolive and gave the stock a “buy” rating in a research note on Friday, July 12th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $73.13.
Hedge funds have recently bought and sold shares of the stock. Krane Funds Advisors LLC acquired a new position in shares of Colgate-Palmolive during the 2nd quarter worth approximately $25,000. Lipe & Dalton acquired a new position in shares of Colgate-Palmolive during the 2nd quarter worth approximately $29,000. Meridian Wealth Management LLC acquired a new position in shares of Colgate-Palmolive during the 1st quarter worth approximately $29,000. Enterprise Trust & Investment Co acquired a new position in shares of Colgate-Palmolive during the 2nd quarter worth approximately $36,000. Finally, WP Advisors LLC acquired a new position in shares of Colgate-Palmolive during the 1st quarter worth approximately $34,000. 75.64% of the stock is currently owned by institutional investors and hedge funds.
Colgate-Palmolive Company Profile
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.
Featured Story: Are sell-side analysts objective?
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.